Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Market price (% of par)
-
84.45%
-
Total 13F principal
-
$799,411,199
-
Principal change
-
+$5,048,367
-
Total reported market value
-
$679,095,809
-
Number of holders
-
65
-
Value change
-
+$6,210,490
-
Number of buys
-
24
-
Number of sells
-
26
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q3 2023
As of 30 Sep 2023,
HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by
65 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$799,411,199
in principal (par value) of the bond.
The largest 10 bondholders included
Voya Investment Management LLC, CAMDEN ASSET MANAGEMENT L P /CA, Wellesley Asset Management, Linden Advisors LP, Invesco Ltd., Davidson Kempner Capital Management LP, CITIGROUP INC, AVIVA PLC, LAZARD ASSET MANAGEMENT LLC, and STATE STREET CORP.
This page lists
65
institutional bondholders reporting positions
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.